Peptide ScheduleTB-500
Benefits
About TB-500
TB-500 is the active fragment of Thymosin Beta-4, a naturally occurring protein involved in tissue repair and regeneration. It promotes angiogenesis, reduces inflammation, and upregulates actin — a cell-building protein critical for healing. Unlike BPC-157, TB-500 works systemically, meaning it doesn't need to be injected near the injury site. It's commonly loaded at higher doses for 4-6 weeks, then maintained at half dose.
Who Should Consider TB-500
- Athletes recovering from soft tissue injuries (tendons, ligaments, muscle tears)
- Post-surgical patients seeking accelerated wound healing
- Individuals with chronic tendinopathy or repetitive strain injuries
- Older adults with impaired healing capacity
- People recovering from traumatic brain injury (TBI) — preclinical evidence only
- Those with fibrotic conditions seeking to reduce scar tissue formation
How TB-500 Works
TB-500 upregulates actin, a key structural protein involved in cell migration, proliferation, and tissue repair. It promotes angiogenesis (new blood vessel formation), reduces inflammation by downregulating inflammatory cytokines, and decreases fibrosis (scar tissue). Its systemic action means it reaches damaged tissue regardless of injection location.
What to Expect
Loading phase begins — 2x/week at full dose. Mild systemic effects may include temporary lethargy or headache. Inflammation reduction may begin within days.
Loading phase continues. Noticeable improvement in pain levels, flexibility, and range of motion around injured areas. New blood vessel formation (angiogenesis) accelerates tissue repair.
End of loading phase. Significant healing progress in soft tissue injuries. Many users report substantially reduced pain and improved function.
Transition to maintenance — half dose, 1x/week. Continued healing support. Reload at full dose if a new injury occurs.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 2mg | 2x/week |
| Moderate | 5mg | 2x/week |
| Aggressive | 7,500mcg | 2x/week |
Note: Loading phase 4-6 weeks at higher dose, then maintenance at half dose weekly. Systemic action; injection site does not need to be near injury.
How to Inject TB-500
Inject subcutaneously or intramuscularly. Injection site does not matter — TB-500 is fully systemic. Abdomen or thigh are common. Rotate sites.
Cycling Protocol
Loading phase: full dose 2x/week for 4-6 weeks. Then maintenance: half dose 1x/week. Repeat loading if needed for new injuries.
Pharmacokinetics
Source: Estimated from animal PK data and limited human phase I data (PMID 34346165); no formal human PK characterization for TB-500 fragment
Pharmacokinetics — Active Dose Over Time
t½ = ~5 hours plasma (functional tissue activity persists 7-10 days)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Side Effects
Headache, mild nausea, lightheadedness. Temporary lethargy during loading phase. Rare: flu-like symptoms.
Contraindications
- Active cancer or personal history of cancer — TB-500 promotes angiogenesis, which may support tumor vascularization and growth
- Pregnancy or breastfeeding — no safety data available in pregnant or lactating individuals
- Active systemic infections — enhanced cell migration could theoretically spread pathogens
- Known hypersensitivity to thymosin beta-4 or any component of the formulation
Drug Interactions
- Anticoagulants (warfarin, heparin, DOACs) — TB-500 promotes angiogenesis and may increase bleeding risk at healing sites
- Other angiogenic healing peptides (BPC-157) — additive angiogenic effects; monitor closely when stacking, though this combination is commonly used
- Immunosuppressants — TB-500 modulates immune cell migration; effect on immunosuppressive therapy is unknown
- Anti-VEGF therapies (bevacizumab) — directly opposes TB-500 mechanism; concurrent use is contraindicated
Storage & Stability
Molecular Profile
Related Peptides
References
- Thymosin Beta 4: A Potential Novel Therapy for Neurotrophic Keratopathy, Dry Eye, and Ocular Surface DiseasesPubMed 27450739
- Thymosin beta4 and cardiac repairPubMed 20536454
- First-in-human phase I study of recombinant human thymosin beta-4 in healthy Chinese volunteersPubMed 34346165
- Thymosin beta-4: a multi-functional regenerative peptide — basic properties and clinical applicationsPubMed 22074294
- Thymosin beta4 is cardioprotective after myocardial infarctionPubMed 17600280